EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Ultra-Low Dose Argatroban in Heparin-Induced Thrombocytopenia with Thrombocytopenia and Hypofibrinogenemia: A Case Report

Chunqian Shi iD, Tong Cai, Mei Yue, Huijuan Ma, Qingfen Qin, Qian Song

TH Open · 11.08.2026 · 10 (CP)

DOI: 10.1055/a-2923-1469 ↗

Kurz gefasst

Fallbericht in der Zeitschrift TH Open, erschienen am 11.08.2026. Verfasst von Chunqian Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical LaboratoryNorth China Medical and Health Group Xingtai General HospitalXingtaiHebei ProvinceChina. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heparin-induced thrombocytopenia (HIT) with thrombosis typically necessitates immediate therapeutic-dose anticoagulation, yet management becomes exceedingly complex when a profound bleeding risk coexists. We report a unique case of serologically confirmed HIT developing during low-molecular-weight heparin prophylaxis following major trauma in a 67-year-old man. On day 10 of heparin exposure, the patient presented with a platelet count declining from 169 × 109/L to 20 × 109/L (91% reduction), hypofibrinogenemia (1.12 g/L), extensive deep vein thrombosis, and pulmonary embolism. Owing to extreme bleeding risk, argatroban initiation was deferred for 48 hours postdiagnosis, then cautiously titrated from 0.08 to 0.67 μg/kg/min guided by dynamic coagulation–fibrinolysis markers (thrombin–antithrombin complex, plasmin–α2-antiplasmin complex, and D-dimer). These markers provided real-time assessment of treatment response, declining substantially prior to platelet count normalization. By day 12 postdiagnosis, platelet count recovered to 176 × 109/L, permitting successful definitive orthopedic surgery on day 13 without bleeding complications. This case illustrates that in HIT with life-threatening thrombosis and extreme bleeding risk, an individualized “start low, go slow” argatroban strategy with delayed initiation achieves effective anticoagulation while minimizing hemorrhagic risk.

Schlagwörter

Stichwörter der Autor:innen

argatrobancoagulation–fibrinolysis markersheparin-induced thrombocytopeniahypofibrinogenemiathrombocytopenia

Autor:innen und Institutionen

  • Department of Clinical LaboratoryNorth China Medical and Health Group Xingtai General HospitalXingtaiHebei ProvinceChina.

ORCID-Profile: Chunqian Shi

Zitieren

APA

Shi, C., Cai, T., Yue, M., Ma, H., Qin, Q., & Song, Q. (2026). Ultra-Low Dose Argatroban in Heparin-Induced Thrombocytopenia with Thrombocytopenia and Hypofibrinogenemia: A Case Report. TH Open, 10(CP). https://doi.org/10.1055/a-2923-1469

Vancouver

Shi C, Cai T, Yue M, Ma H, Qin Q, Song Q. Ultra-Low Dose Argatroban in Heparin-Induced Thrombocytopenia with Thrombocytopenia and Hypofibrinogenemia: A Case Report. TH Open. 2026;10(CP). doi:10.1055/a-2923-1469

BibTeX
@article{Shi2026,
  author = {Shi, Chunqian and Cai, Tong and Yue, Mei and Ma, Huijuan and Qin, Qingfen and Song, Qian},
  title = {Ultra-Low Dose Argatroban in Heparin-Induced Thrombocytopenia with Thrombocytopenia and Hypofibrinogenemia: A Case Report},
  journal = {TH Open},
  year = {2026},
  volume = {10},
  number = {CP},
  doi = {10.1055/a-2923-1469}
}
Kostenlos starten →